Belvedere Trading
TCRR

Belvedere Trading’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Belvedere Trading’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-31,992
Closed -$32K – 1615
2022
Q4 		$32K Buy
31,992
+15,676
+96% +$21.1K ﹤0.01% 746
2022
Q3 		$26K Buy
+16,316
New +$47.3K ﹤0.01% 232

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Belvedere Trading's TCRR Position: Q1 2023 in Review

Belvedere Trading sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q1 2023, closing a stake of 31,992 shares — an estimated $32K sold.

Belvedere Trading first reported a position in TCRR in Q3 2022 and held it in 2 quarters. The position peaked at $32K in Q4 2022. 59 funds tracked by Wall St. Rank hold TCRR as of Q1 2023.

  • Belvedere Trading reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Belvedere Trading sold 31,992 TCR2 Therapeutics Inc. Common Stock shares in Q1 2023, an estimated $32K.
  • Belvedere Trading first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2022 and held it in 2 quarters.
  • Belvedere Trading's TCR2 Therapeutics Inc. Common Stock position peaked at $32K in Q4 2022.
  • 59 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q1 2023.

Based on Belvedere Trading's 13F filing for Q1 2023, filed 15 May 2023.